News | PET-CT | June 12, 2017

FDA Clears Biograph Horizon Flow Edition PET/CT System From Siemens Healthineers

System’s FlowMotion continuous bed motion scanning technology enables personalized PET exam protocols based on patient’s anatomy

Siemens Healthineers announced that the Food and Drug Administration (FDA) has cleared Biograph Horizon Flow edition, a cost-competitive positron emission tomography/computed tomography (PET/CT) system that features the company’s revolutionary FlowMotion continuous bed motion scanning technology. With products such as the Biograph Horizon Flow edition, as well as a new name that underlines the company’s pioneering spirit and engineering expertise, Siemens Healthineers – the separately managed healthcare business of Siemens AG – is helping to enable healthcare providers worldwide to meet current challenges and excel in their respective environments.

Initially introduced on the company’s premium Biograph mCT Flow PET/CT platform in 2013, FlowMotion continuous bed motion technology differs from conventional step-and-shoot PET/CT scanning in that it enables personalized exam protocols based on patient anatomy. These protocols can be configured based on the radiology department’s most commonly scanned indications to support standardization. With the extension of FlowMotion continuous bed motion technology to Biograph Horizon Flow edition scanners, users can define up to four distinct scanning regions, each with a different bed speed. Additionally, specific exam reconstructions can be applied to each scanning region or to multiple regions.  Biograph Horizon Flow edition facilitates high-resolution reconstructions and respiratory gating, which can help improve the ability of clinicians to detect lesions.

In addition to FlowMotion continuous bed motion technology, Biograph Horizon Flow edition includes HD•Chest – another popular feature previously found only on the company’s Biograph mCT family of PET/CT systems – which acquires and processes motion-frozen chest scans five times faster than standard respiratory gating techniques.

“With the addition of Biograph Horizon Flow edition to the Siemens Healthineers PET/CT portfolio, customers tasked with reaching a certain price point no longer need to make compromises in the PET/CT technology they offer patients,” said Doug Darrow, Vice President of Molecular Imaging at Siemens Healthineers North America. ‘The Biograph Horizon Flow edition is the ideal https://www.itnonline.com/channel/pet-ct not only for progressive community hospitals but also for satellite campuses of large healthcare networks that are looking to provide the same premium continuous bed motion technology as their flagship facilities.”

For more information: www.siemens.com/healthineers

Related Content

News | PACS | June 23, 2017
Medidata and Median Technologies announced a new collaboration to streamline the growth and use of medical imaging in...
RamSoft Partners With Gamel to Enhance Patient Care in Peruvian Market
News | PACS | June 23, 2017
RamSoft announced a new partnership with Peru-based medical imaging equipment provider, Gamel. With RamSoft’s...
ClearRead CT Nearing 50 Installations Milestone
News | Computed Tomography (CT) | June 22, 2017
June 22, 2017 — Riverain Technologies announced that it is now processing data from nearly 50...
RadNet Inc. Acquires Equity Stake in Medic Vision
News | Radiation Dose Management | June 21, 2017
June 21, 2017 — RadNet Inc. and Medic Vision Imaging Solutions Ltd.
Carestream Showing New Mobile X-ray System With Carbon Nanotube Technology at AHRA
News | Digital Radiography (DR) | June 20, 2017
June 20, 2017 — Carestream Health will show the DRX-Revolution Nano Mobile...
Combined Optical and Molecular Imaging Could Guide Breast-Conserving Surgery

WLE specimen from a patient with a grade 3, ER-/HER2-, no special type (NST) carcinoma. (A) Cerenkov image; (B) Grey-scale photographic image overlaid with Cerenkov signal. An increased signal from the tumor is visible (white arrows); mean radiance is 871 ± 131 photons/s/cm2/sr, mean TBR is 3.22. Both surgeons measured the posterior margin (outlined in blue) as 2 mm (small arrow); a cavity shaving would have been performed if the image had been available intraoperatively. The medial margin (outlined in green) measured >5 mm by both surgeons. Pathology ink prevented assessing the lateral margin; a phosphorescent signal is visible (open arrows). (C) Specimen radiography image. The absence of one surgical clip to mark the anterior margin, and the odd position of the superior margin clip (white arrow) prevented reliable margin assessment. (D) Combined histopathology image from two adjacent pathology slides on which the posterior margin (bottom of image) and part of the primary tumor are visible (open arrows). The distance from the posterior margin measured 3 mm microscopically (double arrow). The medial margin is > 5 mm (not present in image). Credit: A. D. Purushotham, M.D., King’s College London, UK

News | Nuclear Imaging | June 20, 2017
June 20, 2017 — Breast-conserving surgery (BCS) is the primary treatment for early-stage...
Fujifilm Exhibits Suite of Enterprise Imaging Solutions at SIIM 2017
News | Enterprise Imaging | June 19, 2017
Fujifilm Medical Systems U.S.A. Inc. presented its comprehensive Synapse Enterprise Imaging portfolio at the 2017...
The Magnetom Vida with BioMatrix technology
News | Magnetic Resonance Imaging (MRI) | June 16, 2017
The U.S. Food and Drug Administration (FDA) has cleared the Magnetom Vida 3 Tesla (3T) magnetic resonance imaging (MRI...
A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging

A 77-year-old male with recurrent lymph node and pulmonary metastases detected by Ga-68 PSMA PET/CT but not by conventional imaging. Graphic courtesy of the Department of Nuclear Medicine, Royal North Shore Hospital, Sydney

News | Prostate Cancer | June 15, 2017
An estimated one in seven American men will be affected by prostate cancer in their lifetime. Prostate-specific...
Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer

IMAGE OF THE YEAR: Dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer. Technology of dual-labeled PSMA-inhibitors for PET/CT imaging and fluorescence-guided intraoperative identification of metastases. This work might help to establish a new treatment regimen for more precise and sensitive pre-, intra- and post-therapeutic detection of prostate cancer.

Credit: Courtesy of A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center, Heidelberg, Germany; T. Simpfendörfer, B. Hadaschik, U. Haberkorn, Heidelberg University Hospital, Heidelberg, Germany; PET-image: Afshar-Oromieh et al., EJNMMI 2013; 40(4); STED-image: J. Matthias, German Cancer Research Center.

This study was supported by the VIP+ fund, Federal Ministry of Education & Research (BMBF), Germany.

Scientific Paper 531: “Preclinical evaluation of dual-labeled PSMA-inhibitors for the diagnosis and therapy of prostate cancer.” A. Baranski, M. Schäfer, U. Bauder-Wüst, M. Roscher, J. Schmidt, E. Stenau, L. Maier-Hein, M. Eder, K. Kopka, German Cancer Research Center (DKFZ), Heidelberg, Germany; T. Simpfendörfer, B.  Hadaschik, U. Haberkorn, University Hospital, Heidelberg, Germany. Presented at SNMMI’s 64th Annual Meeting, June 10-14, 2017, Denver, Colo.

News | Prostate Cancer | June 15, 2017
In the battle against metastatic prostate cancer, the removal of lymph node metastases using image-guided surgery may...
Overlay Init